In this episode, host Dr. Fabian Proft explores the most impactful research and updates from the EADV 2024 Congress in Amsterdam. Joining him are distinguished Young GRAPPA members Dr. Dimitri Luz, Dr. Ahmet Uğur, and Dr. Margo Gkini, who each share their expert perspectives on groundbreaking studies and their implications for psoriatic disease care.

• What the latest research reveals about psoriasis pathophysiology.  
• How biologics are impacting long-term treatment safety and efficacy.  
• Insights into the gut-skin connection and its role in inflammation.

• Learn more about GRAPPA: GRAPPA Official Website  
• Discover highlights from the GRAPPA EADV 2024 Congress Highlights.

🎧 Subscribe to Inside GRAPPA on your favorite podcast platform for more updates on cutting-edge research and clinical strategies in psoriasis and psoriatic arthritis. Don't miss the next episode---stay tuned and stay curious!

Hosted on Acast. See acast.com/privacy for more information.

How close are we to predicting psoriatic arthritis (PsA) before it strikes? In this episode of Inside GRAPPA, Dr. Fabian Proft sits down with two esteemed researchers, Dr. Axel Svedbom and Professor Mona Ståhle, from the Karolinska Institute in Stockholm, to discuss their groundbreaking study on predicting PsA in patients with new-onset psoriasis. Funded by the GRAPPA Pilot Research Grant, this project is poised to revolutionize early detection and intervention strategies for psoriatic disease.

Listen as they discuss:  

• The innovative predictive models combining machine learning with clinical data.  
• Key findings, including the significance of arthralgia as a predictive marker for PsA.  
• How their research could reshape clinical practices and improve patient outcomes.

• Dr. Axel Svedbom: Postdoctoral researcher specializing in registry-based research and health economics, with over a decade of focus on psoriasis and psoriatic arthritis.  
• Professor Mona Ståhle: Dermatologist and researcher dedicated to advancing understanding and treatment of psoriatic disease.

• Stay updated with GRAPPA's initiatives: GRAPPA Website.  
• Explore previous episodes of Inside GRAPPA: Podcast Archive.
• 
  

🎙️ Subscribe to Inside GRAPPA and join the conversation!

Hosted on Acast. See acast.com/privacy for more information.

How should musculoskeletal symptoms in psoriasis patients be managed---and who should take the lead? In this episode of Inside GRAPPA, Dr. Mio Nakamura moderates a compelling debate featuring Dr. Laura Savage, Consultant Dermatologist from Leeds Teaching Hospital, UK, and Dr. Fabian Proft, Rheumatologist from Berlin, Germany. Together, they tackle the vital question: Should dermatologists or rheumatologists be in the driver's seat when managing psoriatic arthritis (PsA)?

Listen as they discuss:

•   The role of dermatologists in early detection and PsA prevention.  
•   Rheumatologists' emphasis on precise diagnosis and targeted treatment.  
•   The power of collaborative care in improving patient outcomes.

Join us for an engaging conversation about the challenges and opportunities in PsA management, and how multidisciplinary approaches can lead to better care for patients with psoriatic disease.

•   Dr. Laura Savage: Consultant Dermatologist specializing in psoriatic disease, advocating for early intervention strategies in dermatology.  
•   Dr. Fabian Proft: Rheumatologist with expertise in imaging and precision medicine for inflammatory arthritis.

•   Discover GRAPPA's commitment to collaboration: GRAPPA Website.  
•   Catch up on past episodes of Inside GRAPPA: Podcast Archive.

🎙️ Don't miss this episode filled with expert perspectives on psoriatic disease care. Subscribe to Inside GRAPPA and be part of the conversation!

Hosted on Acast. See acast.com/privacy for more information.

In this insightful episode, host Dr. Sebastian Herrera delves into the critical topic of comorbidities and related conditions in psoriatic disease, alongside experts Professor Kurt de Vlam MD, PhD, Head of Clinic Rheumatology at the University Hospitals Leuven in Belgium and Dr. Alexis Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology at the University of Pennsylvania in the United States.

What's inside this episode?

• Understanding Comorbidities vs. Related Conditions: Discover the distinctions between these two critical aspects and why it's important to differentiate them in psoriatic disease management.
• Expert Insights: Hear about the influence of comorbidities on treatment choices and patient outcomes.
• Impact on Treatment: Learn how related conditions and comorbidities affect therapeutic decisions, including the selection of DMARDs.
• Patient Care: Explore the importance of a comprehensive approach to treating psoriatic disease, addressing both the primary condition and associated health issues.

Key Points & Highlights:

• Definitions and Importance: Clear definitions of comorbidities and related conditions, and their significance in the clinical setting.
• Treatment Influences: How the presence of comorbidities can alter the choice of therapies and the necessity of personalized treatment plans.
• Common Comorbidities: Discussion on obesity, cardiovascular disease, depression, and more, and their implications for patient care.
• Future Directions: The need for ongoing research and proactive management strategies to improve patient outcomes.

Why listen?

• Educational Insight: Gain a deeper understanding of how comorbidities and related conditions impact psoriatic disease.
• Expert Opinions: Benefit from the knowledge and experience of leading specialists in the field.
• Comprehensive Care: Learn about the holistic approach to managing psoriatic disease, ensuring better quality of life for patients.

Stay Connected:

For more intriguing insights and episodes, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share with your colleagues and friends who might benefit from this episode!

Hosted on Acast. See acast.com/privacy for more information.

Today on Inside GRAPPA, host Sebastian Herrera is joined by Lourdes Perez Chada, an Instructor in Dermatology at Harvard Medical School and a clinical investigator at the Brigham and Women’s Hospital in Boston, and Cheryl Rosen who is the Head of the Division of Dermatology,Toronto Western Hospital and University Health Network Hospitals, a Clinician Investigator at Toronto Western Hospital, and a Professor of the Dept of Medicine, University of Toronto.

In this episode, we discuss the importance of nail psoriasis, including the prevalence, manifestations, and diagnosis, and how it affects patients in their daily lives.

Key Topics:

• Prevalence and Diagnosis: Nail psoriasis affects about 50% of patients with psoriasis and up to 90% over their lifetime. The experts discuss clinical diagnostic methods and the challenges in identifying the condition. Tools like biopsies and imaging are rarely used due to their invasiveness.
• Differential Diagnosis: They examine common conditions that can be mistaken for nail psoriasis, including onychomycosis (fungal infections), lichen planus, and alopecia areata.
• Impact on Quality of Life: Nail psoriasis has a significant impact, especially in terms of physical pain, mental health, and daily activities. Patients may experience anxiety and depression, particularly when their hands or feet are affected.
• Association with Psoriatic Arthritis: Nail psoriasis is a risk factor for developing psoriatic arthritis, due to the anatomical connection between the nail and underlying bones. The discussion covers how this link affects prognosis and treatment.
• Treatment Options: Historically difficult to treat, nail psoriasis management ranges from doing nothing for mild cases to topical treatments and biologics. The experts focus on biologics like Ixekizumab and Tofacitinib (Xeljanz), which have shown promise in treating both nail disease and psoriatic arthritis.

Stay Connected 

• For more intriguing insights and episodes, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share with your colleagues and friends who might benefit from this episode!

Hosted on Acast. See acast.com/privacy for more information.

Join us in this episode of Inside GRAPPA, where our host Dr. Sebastian Herrera delves into the complexities of dactylitis in psoriatic disease. Dr. Herrera is joined by two renowned experts, Dr. Philip Helliwell and Dr. Sibel Aydin, who bring their extensive knowledge and insights to this fascinating topic.

• Understanding Dactylitis: Learn about the definition, prevalence, and clinical significance of dactylitis in psoriatic arthritis.
• Differential Diagnosis: Discover the differential diagnoses and the importance of distinguishing dactylitis from other conditions.
• Diagnostic Techniques: Explore the role of clinical examination and ultrasound in diagnosing and understanding the underlying pathology of dactylitis.
• Treatment Approaches: Gain insights into the current treatment recommendations for managing dactylitis in psoriatic disease, including local and systemic therapies.

• Expert Insights: Dr. Helliwell discusses the clinical features, differential diagnosis, and the importance of dactylitis as a severity marker.
• Ultrasound Imaging: Dr. Aydin explains the use of ultrasound in identifying various pathologies associated with dactylitis, including synovitis, tenosynovitis, and entheseal involvement.
• Treatment Strategies: Both experts share their perspectives on the efficacy of different treatments, including the use of local steroid injections and systemic therapies like methotrexate and biologics.

• Educational Value: Enhance your understanding of dactylitis and its management in psoriatic disease.
• Expert Opinions: Benefit from the knowledge and experience of leading experts in the field.
• Practical Insights: Learn practical tips for diagnosing and treating dactylitis effectively.

• For more insightful episodes and updates, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share this episode with colleagues and friends who might find it beneficial!

Hosted on Acast. See acast.com/privacy for more information.

Today on Inside GRAPPA, host Fabian Proft is joined by Professor Elaine Husni and Professor Stefan Siebert to discuss the management of conditions related to psoriatic arthritis (PSA), particularly inflammatory bowel disease (IBD) and uveitis.

In this episode, we discuss treatment modalities, the importance of early diagnosis, and the implications for clinical practice. The experts also delve into future directions for PSA treatment, highlighting the evolving field of biologics and interdisciplinary approaches. This episode offers a comprehensive exploration of managing associated conditions in PSA, emphasizing the importance of personalized treatment strategies.

What's inside this episode?

• Understanding Psoriatic Arthritis: Insights into managing associated conditions like IBD and uveitis.
• Expert Discussions: Professors Husni and Siebert share their experiences and approaches in treating these complex cases.
• Future of Treatment: An overview of emerging therapies and the importance of interdisciplinary collaboration in PSA management.
• Clinical Perspectives: Exploring the impact of early diagnosis and treatment personalization on patient outcomes.

Stay Connected 

For more intriguing insights and episodes, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share with your colleagues and friends who might benefit from this episode!

Hosted on Acast. See acast.com/privacy for more information.

In this insightful episode, our host and moderator Dr. Charlotte Gollins dives deep into the complexities and nuances of the 2022 GRAPPA Treatment Recommendations for the skin psoriasis domain, alongside experts Dr. Kristina Duffin and Dr. Joseph Merola.

What's inside this episode?

• Behind the Scenes: Get an exclusive look into the rigorous process of developing the GRAPPA treatment recommendations.
• Challenges and Innovations: Explore the unique challenges faced in formulating guidelines for a complex disease like psoriatic arthritis.
• Expert Insights: Hear from Dr. Duffin and Dr. Merola as they share their experiences and the key focus areas in the development process of the skin domain.
• Future Directions: Learn about the aspirations for future updates to these crucial guidelines and how they aim to continuously evolve to meet patient needs.

Join us for a deep dive into:

• The multifaceted approach to treating psoriasis.
• Balancing evidence-based guidelines with practical clinical application.
• The ongoing journey to refine and improve treatment recommendations.

Why listen?

• Educational Insight: Understand the latest advancements in psoriasis treatment.
• Expert Opinions: Gain valuable knowledge from leading experts in the field.
• Global Impact: Discover how these guidelines are shaping psoriatic arthritis care worldwide.

Stay Connected:

• For more intriguing insights and episodes, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share with your colleagues and friends who might benefit from this episode!

Hosted on Acast. See acast.com/privacy for more information.

Explore the realm of enthesitis and its treatment advancements in this informative episode of Inside GRAPPA. With renowned experts, Philip Mease (USA) and Dr. Lihi Eder (Canada), we journey through the intricacies of these diseases, emphasizing the manuscript "Management of Enthesitis in Patients with Psoriatic Arthritis." Discover the essence of Enthesitis, the challenges in its diagnosis, and the promising horizon of treatments. Stay curious as we unravel the complexities of this intriguing topic together!

Key Highlights:

Manuscript Spotlight: 

• "Management of Enthesitis in Patients with Psoriatic Arthritis" - A comprehensive paper spotlighting the advancements and current insights on psoriatic arthritis and enthesitis.

Understanding Enthesitis:

• The essence and impact of Enthesitis in the medical landscape.
• The diagnostic challenges and the role of ultrasound in offering a game-changing solution.

Journey through Treatments:

• Historical insights into enthesitis and the tools, like the Leeds Enthesitis Index and SPARC, that have transformed our understanding over the last 25 years.
• The evolution of treatments, what the present offers, and a sneak peek into the future of psoriatic arthritis treatment.

Unveiling the Future:

• The burning questions surrounding the pathophysiology of Enthesitis and the unmet needs in its management.
• The promising direction of current research and what it aims to achieve.

Resources and Links:

• Manuscript: Management of Enthesitis in Patients with Psoriatic Arthritis.
• Organizations: CorEvitas Cohort - Delve deeper into the studies that shape our understanding of enthesitis.

Hosted on Acast. See acast.com/privacy for more information.

Dive deep into the intricate world of psoriasis and psoriatic arthritis with experts Prof. Dafna Gladman and Prof. Ennio Lubrano. This episode focuses on the latest research, insights, and breakthroughs, with an in-depth exploration of the manuscript "Management of Axial Disease in Patients with Psoriatic Arthritis." Join us as we navigate the nuances and challenges of axial psoriatic arthritis, its distinction from ankylosing spondylitis, and the complexities of treatment choices. Stay curious, and let's uncover the mysteries of this fascinating topic together!

Key Highlights:

• Manuscript Spotlight: "Management of Actual Disease in Patients with Psoriatic Arthritis" -- a vital paper highlighting the advancements and current understanding of axial psoriatic arthritis.
• Axial PsA Exploration:
• Historical perspective of Axial PsA and its progression.
• Differences between psoriatic arthritis with axial disease and ankylosing spondylitis.
• Radiographic features, MRI in diagnosis, and the AXIS trial's significance.
• Treatment Landscape:
• The current treatments available and the challenges of determining the best treatment.
• Addressing similarities and differences in treatment approaches for axial psoriatic arthritis and axial spondyloarthritis.
• Future Perspectives:
• The need for further research and clarity in defining axial psoriatic arthritis.
• The anticipation around the STAR study results and their implications.

Resources and Links:

• Organization: Spondyloarthritis Research Consortium Canada (SPARCC).
• Studies:
• AXIS trial (Axial Psoriatic Arthritis)
• The STAR study
• Publication: Article on early stages of axial psoriatic arthritis published in the Annals.
• 
  

Stay Connected: Visit our official GRAPPA website for more resources and episodes.

Hosted on Acast. See acast.com/privacy for more information.